-
Obinutuzumab, sold
under the
brand name
Gazyva among others, is a
humanized anti-CD20
monoclonal antibody used as a
treatment for cancer. It was originated...
- FDA
granted accelerated approval to zanubrutinib, in
combination with
obinutuzumab, for
relapsed or
refractory follicular lymphoma after two or more lines...
-
technology to
afucosylate antibodies; one of its
products in
development was
obinutuzumab,
which gained FDA
approval in
November 2013 for the
treatment of chronic...
- with
obinutuzumab plus
bendamustine followed by
maintenance treatment with
obinutuzumab (if they have not been
treated previously with
obinutuzumab). Other...
-
actively controlled trial of
venetoclax in
combination with
obinutuzumab (VEN+G)
versus obinutuzumab in
combination with
chlorambucil (GClb) in 432 parti****nts...
-
Single Agent and in
Combination With
Obinutuzumab,
Administered After a Fixed,
Single Pre-Treatment Dose of
Obinutuzumab in Parti****nts With Relapsed/Refractory...
- into a
collaboration with
Roche and its
subsidiary GlycArt to
develop obinutuzumab. In
February 2010
Genentech entered into a
collaboration with University...
- non-Hodgkin's
lymphoma (NHL). In
January 2019,
ibrutinib in
combination with
obinutuzumab was
approved for the
treatment of
adults with
previously untreated chronic...
- CD20 is the
target of the
monoclonal antibodies rituximab, ocrelizumab,
obinutuzumab, ofatumumab,
ibritumomab tiuxetan, tositumomab, and ublituximab, which...
-
fully human B cell-depleting agent. Third-generation anti-CD20s such as
obinutuzumab have a
glycoengineered Fc
fragment (Fc) with
enhanced binding to Fc gamma...
